Biovie Inc Stock Price To Sales
| BIVI Stock | USD 2.57 0.13 4.81% |
Biovie Inc fundamentals help investors to digest information that contributes to Biovie's financial success or failures. It also enables traders to predict the movement of Biovie Stock. The fundamental analysis module provides a way to measure Biovie's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biovie stock.
| Last Reported | Projected for Next Year |
Biovie | Price To Sales |
Biovie Inc Company Price To Sales Analysis
Biovie's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Biovie Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Biovie is extremely important. It helps to project a fair market value of Biovie Stock properly, considering its historical fundamentals such as Price To Sales. Since Biovie's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biovie's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biovie's interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Biovie Inc has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Biovie Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biovie's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biovie could also be used in its relative valuation, which is a method of valuing Biovie by comparing valuation metrics of similar companies.Biovie is currently under evaluation in price to sales category among its peers.
Biovie ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biovie's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biovie's managers, analysts, and investors.Environmental | Governance | Social |
Biovie Fundamentals
| Return On Equity | -2.08 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 32.73 M | ||||
| Shares Outstanding | 17.77 M | ||||
| Shares Owned By Insiders | 13.69 % | ||||
| Shares Owned By Institutions | 9.98 % | ||||
| Number Of Shares Shorted | 1.84 M | ||||
| Price To Earning | 18.12 X | ||||
| Price To Book | 3.49 X | ||||
| EBITDA | (31.95 M) | ||||
| Net Income | (32.12 M) | ||||
| Cash And Equivalents | 18.64 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 6.11 M | ||||
| Debt To Equity | 3.34 % | ||||
| Current Ratio | 4.50 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (27.95 M) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (5.08) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 49.04 M | ||||
| Total Asset | 25.21 M | ||||
| Retained Earnings | (334.23 M) | ||||
| Working Capital | 19.55 M | ||||
| Current Asset | 9 K | ||||
| Current Liabilities | 961 K | ||||
| Net Asset | 25.21 M |
About Biovie Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biovie Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovie Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Biovie Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biovie's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biovie Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biovie Inc Stock:Check out Biovie Piotroski F Score and Biovie Altman Z Score analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biovie. If investors know Biovie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biovie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.08) | Return On Assets (0.67) | Return On Equity (2.08) |
The market value of Biovie Inc is measured differently than its book value, which is the value of Biovie that is recorded on the company's balance sheet. Investors also form their own opinion of Biovie's value that differs from its market value or its book value, called intrinsic value, which is Biovie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biovie's market value can be influenced by many factors that don't directly affect Biovie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biovie's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biovie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biovie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.